Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial fibrillation (AF) and the growing geriatric population are the major factors expected to propel the growth of the global left atrial appendage closure devices market. In addition, the rising cases of COVID-19 is resulting in increasing demand for left atrial appendage (LAA) closure devices to ween patients off of anticoagulation and eliminate the need for regular Coumadin clinic visits for INR testing used to maintain the drug at therapeutic levels. This is helping the market to witness a progressive growth in the pandemic crisis.
Conversely, the availability of alternative technology and the high costs associated with the LAA closure devices is likely to hamper the market growth in the near future. The report includes detailed analysis on drivers, restraints, challenges, major segments, growth opportunities and strategic growth by market players to better apprehend the effect of COVID-19 pandemic on the global market.
COVID-19 Impact on Left Atrial Appendage Closure Devices Market Report Highlights:
• The CAGR of the left atrial appendage closure devices market as estimated before the outbreak of COVID-19 pandemic was 23.1% over the forecast period.
• The CAGR of the global industry, as projected post the onset of COVID-19 crisis, is expected to grow at 24% during the forecast period.
• The market size of the left atrial appendage closure devices industry in 2020, as estimated before the COVID-19 pandemic began was $572.9 million.
• The real-time market size in 2020, bearing the after-effects of the COVID-19 pandemic is $585.2 million
Download a sample analysis report on the LAA closure devices market.
Current LAA Closure Market Transformation During COVID-19 Crisis
The LAA closure devices industry is likely to experience a surge in the growth rate during the coronavirus pandemic. The governments of various countries are taking initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices during the pandemic, which is the major factor expected to boost the market growth in 2020. Besides, a number of manufacturers are stressing their activities on product improvements to obtain a strong position and sustain in the global market in coronavirus emergency.
For instance, in February 2020, Abbott received the U.S. Food and Drug Administration (FDA) approval for its newly innovated Amplatzer Amulet Left Atrial Appendage Occluder, which is designed for AF patients. This is expected to create lucrative opportunities in the market in the trying times.
Post-Pandemic LAA Closure Market Landscape
As per the report, the global LAA closure devices market is anticipated to witness a tremendous growth even after the COVID-19 pandemic. The continuous advancements in technology, government support for medical device approvals, rise in number of ambulatory clinical centers globally, and developments by prominent market players are the major factors expected to bolster the market growth.
The key players operating in the global industry include:
• Boston Scientific Corp.
• SentreHEART Inc.
• AtriCure Inc.
• Occlutech
• Abbott
• Lifetech Scientific
• Aegis Medical Group.
• Cardia Inc.
• Johnson & Johnson Services Inc.
• Biosense Webster Inc.
The report also summarizes other important aspects of the key players including Financial Performance, Product Portfolio, SWOT analysis, and Recent Strategic moves and developments.
Read more about the thee most commonly used LAA closure devices across the globe are the Watchman, Lariat and the Amplatzer.
Research Dive is a market research firm based in Pune, India. Scrutinizing relevant news releases, government publications, decades of trade data, and technical and white papers, Research Dive delivers the required services to its clients well within the required timeframe.
For more information: www.researchdive.com
Related LAA Occlusion Device Content:
AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
Conformal Medical Secures $85 Million in Funding for Left Atrial Appendage Occluder Trial
VIDEO: Overview of LAA Occlusion Using the Watchman FLX
FDA Clears Next-generation Watchman FLX Left Atrial Appendage Occluder
Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial
First-Of-Its-Kind, No-Implant LAA Occluder Noted for Innovation at 2019 ICI Meeting
April 18, 2024 
